Abdel-Wahab, A., Shafey, D., Sharaf, S., Mohsen, K., Allam, D., Elkhadry, S., Gouda, M. (2024). Intranasal versus intradermal immunoprotective effect of maltodextrin nanoparticles loaded with SAG1 against toxoplasmosis in murine model. Parasitologists United Journal, 17(3), 189-195. doi: 10.21608/puj.2024.310600.1260
Ayman Abdel-Wahab; Dalia Shafey; Soraya Sharaf; Khloud Mohsen; Dina Allam; Sally Elkhadry; Marwa Gouda. "Intranasal versus intradermal immunoprotective effect of maltodextrin nanoparticles loaded with SAG1 against toxoplasmosis in murine model". Parasitologists United Journal, 17, 3, 2024, 189-195. doi: 10.21608/puj.2024.310600.1260
Abdel-Wahab, A., Shafey, D., Sharaf, S., Mohsen, K., Allam, D., Elkhadry, S., Gouda, M. (2024). 'Intranasal versus intradermal immunoprotective effect of maltodextrin nanoparticles loaded with SAG1 against toxoplasmosis in murine model', Parasitologists United Journal, 17(3), pp. 189-195. doi: 10.21608/puj.2024.310600.1260
Abdel-Wahab, A., Shafey, D., Sharaf, S., Mohsen, K., Allam, D., Elkhadry, S., Gouda, M. Intranasal versus intradermal immunoprotective effect of maltodextrin nanoparticles loaded with SAG1 against toxoplasmosis in murine model. Parasitologists United Journal, 2024; 17(3): 189-195. doi: 10.21608/puj.2024.310600.1260
Intranasal versus intradermal immunoprotective effect of maltodextrin nanoparticles loaded with SAG1 against toxoplasmosis in murine model
1Departments of Clinical and Molecular Parasitology , National Liver Institute University , Menoufia, Egypt
2Departments of Clinical and Molecular Parasitology,National Liver Institute ,Menoufi University, Menoufia, Egypt
3Departments of Pathology Faculty of Medicine , Menoufia, Egypt
4Departments of Medicine , National Liver Institute , Menoufi University , Menoufia, Egypt
5Departments of Clinical and Molecular Parasitology , National Liver Institute , Menoufia University , Menoufia, Egypt
Abstract
Background: Until now, there is no available efficient vaccine against toxoplasmosis, and the current medications have adverse side effects. Therefore, the search for prophylactic strategies against toxoplasmosis is mandatory. Objective: To evaluate the immunoprotection potential activity of the immunogenic T. gondii surface antigen 1 (SAG1) combined with maltodextrin nanoparticles (MNPs) against toxoplasmosis. A secondary objective is to assess the most efficient route of administration, intranasal (IN) or intradermal (ID). Material and Methods: This study was carried out on 50 Swiss albino mice that were equally divided into 5 groups: negative and positive controls, ID immunized with SAG1, IN immunized with SAG1-loaded MNPs, and ID immunized with SAG1-loaded MNPs. Brain cyst counting, histopathological examination, and measurement of immunoglobulins G, and A, and interleukins 10, and 12 levels were used to assess the immunoprotective effects SAG1-loaded MNPs. Results: The efficacy of immunization with SAG1 was enhanced after loading it on MNPs with significant reduction rate of brain cyst count: 89.76% in the ID immunized group, and 77.46% in the IN immunized group. Moreover, SAG1-loaded MNPs IN immunized group showed the least pathological changes and the highest levels of anti-T. gondii IgG with the highest levels of cytokines (IL-10 and IL-12). Conclusion: Maltodextrin NPs are a promising effective delivery tool for SAG1. Since IN route is a needlefree method of administration, it is preferred than ID route.
View on SCiNiTO
Top